COMP <GO>
SLS vs XERS // EV/EBITDA & P/E VALUATION
SELLAS Life Sciences Group Inc. (NASDAQ) VS. Xeris Biopharma Holdings Inc. (NASDAQ) • 15-METRIC TALLY: SLS 1
— XERS 4
■ METRIC PARITY
LAST: $8.55 (-11.67%) • MKT CAP: $1.95B
valuation
—
LAST: $10.17 (-5.04%) • MKT CAP: $1.95B
valuation
83.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLS VS. XERS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SLS | XERS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.80% | 16.00% | -37.80 | XERS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 83.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | 1.46% | -2.84 | XERS | /fcf-yield <GO> |
| Operating Margin | — | 8.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 0.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 43.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.11 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | XERS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.8 | 59.7 | -19.90 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $1.95B | $2.2M | SLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SLS REV | XERS REV | SLS GROSS % | XERS GROSS % | SLS FCF | XERS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $79.2M | $291.8M | — | — | -$28.4M | $28.6M |
| FY 2024 | $88.2M | $203.1M | — | — | -$35.4M | -$37.0M |
| FY 2023 | $106.0M | $163.9M | — | — | -$31.4M | -$47.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLS // BETA —
XERS // BETA —